PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Study Contact (Please Do Not Disclose Personal Information)
- Phone Number: See Email
- Email: clinicaltrials@preludetx.com
Study Locations
-
-
-
Bordeaux, France, 33000
- lnstitut Bergonie Centre Regionale de Lutte Contre le cancer, Service Oncologie-Medicale
-
Lyon, France, 69373
- Centre Léon Bérard
-
Marseille, France, 13009
- lnstitut Paoli Calmettes
-
Toulouse, France, 31059
- Oncopole Claudius Regaud IUCT ONCOPOLE
-
Villejuif, France, 94805
- Institut Gustave Roussy
-
-
-
-
-
Leiden, Netherlands, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 119074
- National University Hospital
-
Singapore, Singapore, Singapore, 168583
- National Cancer Centre Singapore
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron
-
-
Barcelona
-
Barcelona, Barcelona, Spain, 08023
- START Barcelona - HM Nou Delfos
-
-
Madrid
-
Madrid, Madrid, Spain, 28040
- START MADRID - FJD Hospital Universitario Fundacion Jimenez Diaz
-
Madrid, Madrid, Spain, 28050
- Hospital Universitario HM Sanchinarro
-
-
-
-
California
-
Sacramento, California, United States, 95817
- University of California, Davis Comprehensive Cancer Center
-
Santa Monica, California, United States, 90404
- UCLA Hematology/Oncology - Santa Monica
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Smilow Cancer Hospital Phase 1 Unit
-
-
Florida
-
Celebration, Florida, United States, 34747
- AdventHealth Medical Group Oncology Research at Celebration
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic, Jacksonville
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic, Rochester
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University School of Medicine - Siteman Cancer Center
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10016
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
New York, New York, United States, 10032
- New York Presbyterian Hospital - Columbia University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Institute Franz Clinic
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- NEXT Virginia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures
- Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancy with any mutation of SMARCA4 (dose escalation and combination cohorts) and loss of function mutation of SMARCA4 (backfill cohorts) by local testing that have either progress on or ineligible for standard of care therapy
- Must have measurable or non-measureable (but evaluable) disease per RECIST v1.1 for dose escalation and combination cohorts
- Must have measureable diseases per RECIST v1.1 for backfill cohort
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Willing to provide either archival or fresh tumor tissue sample
- Adequate organ function (hematology, renal, and hepatic)
Exclusion Criteria:
- Participants with solid tumors with known concomitant SMARCA2 mutation or loss of protein expression
- Clinically significant or uncontrolled cardiac disease, uncontrolled electrolyte disorders, uncontrolled or symptomatic central nervous system (CNS) metastases or leptomeningeal disease
- History of another malignancy within 3 years except for adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancies, or malignancies previously treated with curative intent and not on active therapy or expected to require treatment or recurrence during the study
- Concurrent treatment with strong or moderate CYP3A4 inhibitor or inducer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PRT3789 Monotherapy
PRT3789 will be administered by intravenous infusion
|
PRT3789 will be administered by intravenous infusion
|
|
Experimental: PRT3789/Docetaxel Combination
PRT3789 and Docetaxel will be administered by intravenous infusions
|
PRT3789 will be administered by intravenous infusion
Docetaxel will be administered by intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxel
Time Frame: Baseline through Day 21
|
Dose limiting toxicities will be evaluated over the 21-day observation period
|
Baseline through Day 21
|
|
Safety and tolerability of PRT3789 monotherapy and in combination with docetaxel: AEs, CTCAE Assessments
Time Frame: Baseline through approximately 3 years
|
Safety and tolerability will be evaluated by incidence of DLTs, laboratory measurements, dose interruption, modification, and discontinuation due to adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
|
Baseline through approximately 3 years
|
|
Maximum tolerated dose (MTD)/ Recommended phase 2 dose (RP2D) of PRT3789 monotherapy and in combination with docetaxel
Time Frame: Baseline through approximately 3 years
|
The MTD/RP2D will be established for further investigation in participants with advanced solid tumors
|
Baseline through approximately 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of PRT3789 monotherapy and in combination with docetaxel: Objective response rate (ORR)
Time Frame: Baseline through approximately 3 years
|
Best overall response of either complete response (CR) or partial response (PR), as assessed by the investigator per RECIST v1.1
|
Baseline through approximately 3 years
|
|
Efficacy of PRT3789 monotherapy and in combination with docetaxel: Progression-free survival (PFS)
Time Frame: Baseline through approximately 3 years
|
Duration from Day 1 to the earliest date of first disease progression, as assessed by the investigator per RECIST v1.1, discontinuation because of disease progression, or death due to any cause
|
Baseline through approximately 3 years
|
|
Efficacy of PRT3789 monotherapy and in combination with docetaxel: Clinical benefit rate (CBR)
Time Frame: Baseline through approximately 3 years
|
Best overall response of CR, PR, or durable stable disease (24 weeks or longer duration), as assessed by the investigator per RECIST v1.1
|
Baseline through approximately 3 years
|
|
Efficacy of PRT3789 monotherapy and in combination with docetaxel: Duration of response (DOR)
Time Frame: Baseline through approximately 3 years
|
Duration from time of first observed response (CR or PR) to the earliest date of disease progression, as assessed by the investigator per RECIST v1.1, or death due to any cause
|
Baseline through approximately 3 years
|
|
Pharmacokinetic profile of PRT3789 monotherapy and in combination with docetaxel: Maximum observed plasma concentration
Time Frame: Baseline through approximately 3 years
|
Pharmacokinetics will be calculated including the maximum observed plasma concentration
|
Baseline through approximately 3 years
|
|
Pharmacokinetic profile of PRT3789 monotherapy and in combination with docetaxel: Area under the curve
Time Frame: Baseline through approximately 3 years
|
Pharmacokinetics will be calculated including the area under the plasma concentration versus time curve (AUC)
|
Baseline through approximately 3 years
|
|
Pharmacodynamic effect of PRT3789 monotherapy and in combination with docetaxel: Target engagement
Time Frame: Baseline through approximately 3 years
|
Pharmacodynamic effect of PRT3789 monotherapy and in combination with docetaxel demonstrating target engagement by assessment of SMARCA2 protein in peripheral blood mononuclear cells (PBMCs) and tumor tissue
|
Baseline through approximately 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRT3789-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.